17,261 trials
Age Related Macular Degeneration
Primary: Mean Change in Visual Acuity (VA) From Baseline at Month 6 — 6.1; 2.0 ETDRS Letters
High Risk Non-Hodgkin's Lymphoma
Primary: Assess the Efficacy of Combination Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma — 6 Participants
Prostate Cancer
Primary: Define the PSA Response Rate. — 5; 17; 25 Participants
Autistic Disorder
Primary: Cognitive Assessment: TMT — 118.3; 104.7 seconds
Herpes Zoster
Primary: Cell-Mediated Immunity (CMI) in Terms of Frequencies of Antigen-specific CD4 T Cells — 726.19; 567.52 cells/million T-cells
Systemic Sclerosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 71 Adverse Events
Bronchiolitis Obliterans
Primary: Number of Subjects Who Failed Treatment — 2 Participants
Influenza
Primary: Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain — 5.1; 5.6; 5.3; 5.2 Titers
Diabetes Mellitus, Type 2
Primary: Baseline Hemoglobin A1c (HbA1c) — 8.08; 8.01; 7.88; 8.13 Percent
Mouth Neoplasms · Oropharyngeal Neoplasms · Laryngeal Neoplasms
Primary: Efficacy of Mean Pre-therapy FLT Uptake (SUVmean) in Predicting Progression Free Survival (PFS) — 4.23 standardized uptake value (SUV) — p=0.08
Malignant Melanoma
Primary: Percentage of Participants That Experienced a Dose Limiting Toxicity (DLT) — 0; 17 percentage of participants
Menopausal and Female Climacteric States
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) and Number of Participants With Mild, Moderate and Severe AE — 54; 52; 45; 51 Participants
Blood Cancer · Leukemia
Primary: Acute Graft vs Host Disease (GvHD) — 2.7 percentage of participants
Heart Failure · Diastolic Heart Failure
Primary: Change in Peak Oxygen Uptake (VO2) From Baseline Upto 1 Week of Administration for Each Dose — 1.16; 1.49; 1.20; 1.44 L/min
Cannabis Dependence
Primary: Tolerability — 0; 0; 0 Participants